Literature DB >> 29617256

Schizophrenia.

Richard Barnett.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29617256     DOI： 10.1016/S0140-6736(18)30237-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial.

Authors:  Cheng Zhu; Xiaoni Guan; Yuechan Wang; Jiahong Liu; Thomas R Kosten; Meihong Xiu; Fengchun Wu; Xiangyang Zhang
Journal:  Neurotherapeutics       Date:  2022-04-25       Impact factor: 6.088

2.  Cognitive Enhancing Effect of High-Frequency Neuronavigated rTMS in Chronic Schizophrenia Patients With Predominant Negative Symptoms: A Double-Blind Controlled 32-Week Follow-up Study.

Authors:  Mei Hong Xiu; Heng Yong Guan; Jian Min Zhao; Ke Qiang Wang; Yan Fen Pan; Xiu Ru Su; Yu Hong Wang; Jin Ming Guo; Long Jiang; Hong Yu Liu; Shi Guang Sun; Hao Ran Wu; Han Song Geng; Xiao Wen Liu; Hui Jing Yu; Bao Chun Wei; Xi Po Li; Tammy Trinh; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-03-17       Impact factor: 9.306

3.  Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017.

Authors:  Hairong He; Qingqing Liu; Ning Li; Liyang Guo; Fengjie Gao; Ling Bai; Fan Gao; Jun Lyu
Journal:  Epidemiol Psychiatr Sci       Date:  2020-01-13       Impact factor: 6.892

4.  The Variants at APOA1 and APOA4 Contribute to the Susceptibility of Schizophrenia With Inhibiting mRNA Expression in Peripheral Blood Leukocytes.

Authors:  Yao Fan; Jun Gao; Yinghui Li; Xuefei Chen; Ting Zhang; Weiyan You; Yong Xue; Chong Shen
Journal:  Front Mol Biosci       Date:  2021-12-06

5.  Association between Changes in Total Antioxidant Levels and Clinical Symptom Improvement in Patients with Antipsychotic-Naïve First-Episode Schizophrenia after 3 Months of Risperidone Monotherapy.

Authors:  Keqiang Wang; Meihong Xiu; Xiuru Su; Fengchun Wu; Xiangyang Zhang
Journal:  Antioxidants (Basel)       Date:  2022-03-28

6.  Prevalence of Heavy Menstrual Bleeding and Its Associated Cognitive Risks and Predictive Factors in Women With Severe Mental Disorders.

Authors:  Jianmin Shan; Hongjun Tian; Chunhua Zhou; Haibo Wang; Xiaoyan Ma; Ranli Li; Haiping Yu; Guangdong Chen; Jingjing Zhu; Ziyao Cai; Chongguang Lin; Langlang Cheng; Yong Xu; Sha Liu; Congpei Zhang; Qinghua Luo; Yunshu Zhang; Shili Jin; Chuanxin Liu; Qiuyu Zhang; Luxian Lv; Lei Yang; Jiayue Chen; Qianchen Li; Wei Liu; Weihua Yue; Xueqin Song; Chuanjun Zhuo
Journal:  Front Pharmacol       Date:  2022-07-13       Impact factor: 5.988

7.  Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study.

Authors:  Xiaoni Guan; Jing Xu; Meihong Xiu; Xirong Li; Haixia Liu; Fengchun Wu
Journal:  CNS Neurosci Ther       Date:  2022-06-29       Impact factor: 7.035

8.  Repetitive transcranial magnetic stimulation for psychiatric symptoms in long-term hospitalized veterans with schizophrenia: A randomized double-blind controlled trial.

Authors:  Xiuru Su; Long Zhao; Yujie Shang; Yingnan Chen; Xiaowen Liu; Xuan Wang; Meihong Xiu; Huijing Yu; Lijun Liu
Journal:  Front Psychiatry       Date:  2022-09-23       Impact factor: 5.435

9.  Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study.

Authors:  Xi Rong Li; Mei Hong Xiu; Xiao Ni Guan; Yue Chan Wang; Jun Wang; Edison Leung; Xiang Yang Zhang
Journal:  Neurotherapeutics       Date:  2021-03-31       Impact factor: 7.620

10.  miRNA-Coordinated Schizophrenia Risk Network Cross-Talk With Cardiovascular Repair and Opposed Gliomagenesis.

Authors:  Hongbao Cao; Ancha Baranova; Weihua Yue; Hao Yu; Zufu Zhu; Fuquan Zhang; Dongbai Liu
Journal:  Front Genet       Date:  2020-03-04       Impact factor: 4.599
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.